Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.

05/26/2026, 2:29 PM • The Motley Fool

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

04/29/2026, 1:00 PM • GlobeNewswire

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

04/06/2026, 1:00 PM • GlobeNewswire

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Deerfield Management Company increased its stake in Vera Therapeutics by 418,538 shares during Q4 2025, bringing its total position to $205.58 million (2.6% of fund AUM). Vera's stock has surged 50% over the past year as its lead drug candidate atacicept approaches an FDA decision on July 7, 2026, for treating IgA nephropathy. The company has sufficient cash reserves to fund operations through a potential approval and U.S. launch.

03/13/2026, 10:36 AM • The Motley Fool

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics announced the appointment of Christopher Hite, Executive Vice President and Vice Chairman of Royalty Pharma, to its Board of Directors. Hite brings over 25 years of biopharmaceutical industry experience and will serve as an independent board member as the company prepares for the potential launch of atacicept, its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy treatment.

03/05/2026, 9:00 AM • GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics plans to raise approximately $261 million through a public offering of 6,138,108 shares of Class A common stock at $42.50 per share, with underwriters led by J.P. Morgan and Goldman Sachs.

12/09/2025, 8:57 PM • GlobeNewswire

BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus Treatment

The BK virus infection market is experiencing growth due to increasing organ transplant procedures, lack of FDA-approved drugs, and rising awareness. Innovative therapies and personalized medicine approaches are emerging to address treatment challenges.

11/21/2025, 10:50 AM • GlobeNewswire

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.

11/07/2025, 6:27 PM • GlobeNewswire

Vera (VERA) Q2 Net Loss Widens 127%

Vera Therapeutics reported a wider net loss of $76.5 million in Q2 2025, with significant progress on its lead drug atacicept for treating Immunoglobulin A Nephropathy (IgAN). The company showed positive clinical trial results and plans to submit a Biologics License Application to the FDA in Q4 2025.

08/06/2025, 2:05 AM • The Motley Fool

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics granted stock options and restricted stock units to 15 new employees, with options to purchase 133,500 shares and RSUs for 73,695 shares, vesting over four years.

07/10/2025, 7:05 PM • GlobeNewswire